激素受体阳性乳腺癌的辅助剂量密集化疗
C9741试验12年随访显示,剂量密集化疗较常规化疗改善淋巴结阳性乳腺癌患者的无病生存(HR 0.77)和总生存(HR 0.80),ER+与ER-亚组均获益。SET2,3检测显示低内分泌转录活性可预测剂量密集化疗获益,且不依赖肿瘤负荷、分子亚型或绝经状态。
要点
- 剂量密集化疗较常规化疗改善整体人群DFS(HR 0.77)和OS(HR 0.80)。
- ER+与ER-亚组均见剂量密集化疗获益,治疗臂与ER状态无显著交互作用。
- 低SET2,3状态预后差,但也预测剂量密集化疗获益(DFS交互P=0.0998;OS交互P=0.027)。
核心结论
- 12年随访证实,辅助剂量密集化疗对淋巴结阳性乳腺癌具有持续长期获益。
- SET2,3可识别从剂量密集化疗获益的ER+乳腺癌患者,该获益由癌组织低内分泌活性预测,而非肿瘤负荷、分子亚型或绝经状态。
研究设计与样本
- C9741试验将1973例患者随机分配至剂量密集化疗或常规化疗。
- 在682份ER+癌组织库存RNA样本上检测SET2,3。
- 采用Cox模型估计长期无病生存和总生存的风险比及预测交互作用。
主要发现
- 剂量密集化疗使整体研究人群DFS改善23%(HR 0.77,95%CI 0.66至0.90),OS改善20%(HR 0.80,95%CI 0.67至0.95)。
- ER+和ER-亚组均见剂量密集治疗获益,治疗臂与ER状态间无显著交互作用。
- 低SET2,3状态预后差,但也预测剂量密集化疗后结局改善(DFS交互P=0.0998;OS交互P=0.027),且不依赖绝经状态。
- 低内分泌转录活性预测剂量密集化疗获益,而肿瘤负荷和增殖驱动的分子亚型分类特征则不能预测。
关键数值与推荐
- SET2,3低状态预测剂量密集化疗获益,DFS交互P=0.0998,OS交互P=0.027。
- 整体人群DFS的HR为0.77(95%CI 0.66至0.90),OS的HR为0.80(95%CI 0.67至0.95)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: In light of evolving evidence that some patients with node-positive estrogen receptor-positive (ER+) disease may receive less benefit from chemotherapy, this study reports 12-year outcomes of the C9741 trial overall, and by the sensitivity to endocrine therapy (SET2,3) test index, a biomarker measuring endocrine transcriptional activity, to identify patients most likely to benefit from dose-dense chemotherapy. METHODS: In all, 1,973 patients were randomly assigned to dose-dense versus conventional chemotherapy. Hazard ratios (HRs) for prognosis and for predictive interaction with chemotherapy schedule were estimated from Cox models of long-term disease-free survival (DFS) and overall survival (OS). SET2,3 was tested on the 682 banked RNA samples from ER+ cancers. RESULTS: Dose-dense chemotherapy improved DFS in the overall study population by 23% (HR, 0.77 [95% CI, 0.66 to 0.90]) and OS by 20% (HR, 0.80 [95% CI, 0.67 to 0.95]); the benefits of dose-dense therapy were seen for ER+ and ER-negative subsets, without significant interaction between treatment arm and ER status. Low SET2,3 status was highly prognostic, but also predicted improved outcomes from dose-dense chemotherapy (interaction P = .0998 for DFS; 0.027 for OS), independent of menopausal status. Specifically, low endocrine transcriptional activity predicted benefit from dose-dense chemotherapy, whereas tumor burden and proliferation-driven signatures for molecular subtype classification did not. CONCLUSION: At 12-year follow-up, C9741 confirmed the sustained long-term benefit of adjuvant dose-dense chemotherapy for node-positive breast cancer. SET2,3 identified patients with ER+ breast cancer who benefited from dose-dense chemotherapy, and specifically, this benefit was predicted by low endocrine activity in the cancer, rather than tumor burden, molecular subtype, or menopausal status.
引用
- Metzger Filho O, Ballman K, Campbell J, et al. Adjuvant Dose-Dense Chemotherapy in Hormone Receptor-Positive Breast Cancer. J Clin Oncol. 2025. PMID: 39746162. doi:10.1200/JCO-24-01875
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。